Related Experiment Video

Updated: Jun 22, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Targeting mitochondrial apoptosis by betulinic acid in human cancers

Simone Fulda1, Guido Kroemer

  • 1University Children's Hospital, Eythstr. 24, D-89075 Ulm, Germany. simone.fulda@uniklinik-ulm.de

Drug Discovery Today
|June 13, 2009
PubMed

Insights

Betulinic acid (BA) shows potent anticancer properties by directly triggering apoptosis through mitochondrial damage. Its targeted action spares normal cells, offering a promising therapeutic window for drug-resistant cancers.

Area of Science:

  • Natural Products Chemistry
  • Mitochondrial Biology
  • Cancer Therapeutics

Background:

  • Betulinic acid (BA) is a pentacyclic triterpene with demonstrated antitumor activities.
  • Its anticancer effects are attributed to the induction of apoptosis via mitochondrial membrane permeabilization.
  • BA exhibits selective toxicity, sparing non-neoplastic cells and normal tissues, suggesting a therapeutic window.

Purpose of the Study:

  • To explore the potential of betulinic acid as an anticancer therapeutic.
  • To investigate the mechanism of BA-induced apoptosis, focusing on mitochondrial pathways.
  • To highlight BA's promise in overcoming conventional chemotherapy resistance.

Main Methods:

  • Literature review of studies on betulinic acid's biological activities.
  • Analysis of research on the molecular mechanisms of BA-induced apoptosis.
  • Evaluation of BA's efficacy and selectivity against various cancer types.

Main Results:

  • Betulinic acid directly induces apoptosis by permeabilizing mitochondrial membranes.
  • BA demonstrates potent cytotoxicity against diverse cancer cell lines.
  • Normal cells and tissues show relative resistance to BA, confirming its therapeutic window.

Conclusions:

  • Betulinic acid is a promising mitochondrion-targeted agent for cancer therapy.
  • Its ability to induce apoptosis and overcome drug resistance warrants further investigation.
  • BA represents a novel therapeutic strategy for human cancers, particularly those resistant to conventional treatments.

More Related Videos

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro13:20

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro

Published on: July 17, 2018

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...